SCHEMBL5134835

SCHEMBL5134835

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccccc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
TSHR P16473 2/20 0.40
CRHR1 P34998 3/20 0.38
HSD11B1 P28845 2/20 0.37
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
ATM Q13315 1/20 0.35
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650635 0.93 C5AR1 (0.41) C5AR1TSHRCRHR1HSD11B1KDM4E
SCHEMBL5136687 0.92 C5AR1 (0.43) C5AR1TSHRCRHR1HSD11B1SLC6A2
SCHEMBL5136609 0.92 C5AR1 (0.42) C5AR1TSHRHSD11B1KDM4EALDH1A1
SCHEMBL652182 0.92 C5AR1 (0.41) C5AR1TSHRCRHR1ALDH1A1
SCHEMBL5135263 0.91 C5AR1 (0.42) C5AR1TSHRCRHR1HSD11B1SLC6A2
SCHEMBL5136285 0.91 C5AR1 (0.42) C5AR1TSHRCRHR1HSD11B1SLC6A2
SCHEMBL651879 0.91 C5AR1 (0.43) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL648114 0.90 C5AR1 (0.43) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL648158 0.89 C5AR1 (0.41) C5AR1TSHRCRHR1HSD11B1KDM4E
SCHEMBL651094 0.89 TSHR (0.50) C5AR1TSHRHSD11B1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed